Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis

Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bethge, Johannes, Meffert, Silvia, Ellrichmann, Mark, Conrad, Claudio, Nikolaus, Susanna, Schreiber, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306500/
https://www.ncbi.nlm.nih.gov/pubmed/28243458
http://dx.doi.org/10.1136/bmjgast-2016-000127
_version_ 1782507202283569152
author Bethge, Johannes
Meffert, Silvia
Ellrichmann, Mark
Conrad, Claudio
Nikolaus, Susanna
Schreiber, Stefan
author_facet Bethge, Johannes
Meffert, Silvia
Ellrichmann, Mark
Conrad, Claudio
Nikolaus, Susanna
Schreiber, Stefan
author_sort Bethge, Johannes
collection PubMed
description Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA.
format Online
Article
Text
id pubmed-5306500
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53065002017-02-27 Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis Bethge, Johannes Meffert, Silvia Ellrichmann, Mark Conrad, Claudio Nikolaus, Susanna Schreiber, Stefan BMJ Open Gastroenterol Inflammatory Bowel Disease Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA. BMJ Publishing Group 2017-02-08 /pmc/articles/PMC5306500/ /pubmed/28243458 http://dx.doi.org/10.1136/bmjgast-2016-000127 Text en © 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Inflammatory Bowel Disease
Bethge, Johannes
Meffert, Silvia
Ellrichmann, Mark
Conrad, Claudio
Nikolaus, Susanna
Schreiber, Stefan
Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
title Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
title_full Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
title_fullStr Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
title_full_unstemmed Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
title_short Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
title_sort combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
topic Inflammatory Bowel Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306500/
https://www.ncbi.nlm.nih.gov/pubmed/28243458
http://dx.doi.org/10.1136/bmjgast-2016-000127
work_keys_str_mv AT bethgejohannes combinationtherapywithvedolizumabandetanerceptinapatientwithpouchitisandspondylarthritis
AT meffertsilvia combinationtherapywithvedolizumabandetanerceptinapatientwithpouchitisandspondylarthritis
AT ellrichmannmark combinationtherapywithvedolizumabandetanerceptinapatientwithpouchitisandspondylarthritis
AT conradclaudio combinationtherapywithvedolizumabandetanerceptinapatientwithpouchitisandspondylarthritis
AT nikolaussusanna combinationtherapywithvedolizumabandetanerceptinapatientwithpouchitisandspondylarthritis
AT schreiberstefan combinationtherapywithvedolizumabandetanerceptinapatientwithpouchitisandspondylarthritis

Ejemplares similares